<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216486</url>
  </required_header>
  <id_info>
    <org_study_id>MBPS208</org_study_id>
    <nct_id>NCT03216486</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta</brief_title>
  <acronym>METEOROID</acronym>
  <official_title>A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone
      in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT
      scanner. Participants will be treated for 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Administrative Reason
  </why_stopped>
  <start_date type="Anticipated">October 31, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in radial Trabecular Volumetric Bone Mineral Density (mgHA/cm3)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in radial bone strength on Finite Element Analysis (N)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tibial Trabecular Volumetric Bone Mineral Density (mgHA/cm3)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tibial bone strength on Finite Element Analysis (N)</measure>
    <time_frame>12 months</time_frame>
    <description>High Resolution Peripheral Quantitative Computated Tomography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>BPS804 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPS804 IV Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPS804</intervention_name>
    <description>IV administration of BPS804 in 5% Dextrose solution</description>
    <arm_group_label>BPS804 Dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a clinical diagnosis of OI Type I, III or IV

          -  Capable of giving signed consent

        Exclusion Criteria:

          -  History of skeletal malignancies or other bone diseases (other than OI)

          -  History of endocrine or thyroid/parathyroid conditions that could affect bone
             metabolism

          -  Treatment with bisphosphonates within 3 months of randomisation

          -  Treatment with teraparatide, denosomab or other anabolic/antiresorbative medications
             within 6 months of randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reid Sutton, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

